NCT03959514 is a Phase 1 clinical trial of NovoRapid in Diabetes Mellitus, Type 1, sponsored by Arecor Limited.

Who is sponsoring NCT03959514?

NCT03959514 is sponsored by Arecor Limited.

What drugs are being tested in NCT03959514?

Interventions in NCT03959514: NovoRapid, Fiasp, AT247.

What condition does NCT03959514 study?

NCT03959514 studies Diabetes Mellitus, Type 1.

Is NCT03959514 still recruiting?

NCT03959514 is currently completed. Last updated 30 September 2019.

Last reviewed 2019-09-30 · How we verify

NCT03959514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Completed Phase 1 Last updated 30 September 2019

What this trial tests

Phase 1 trial testing NovoRapid in Diabetes Mellitus, Type 1 in 18 participants. Completed in 8 August 2019.

Timeline

12 April 2019

Primary endpoint
30 July 2019

8 August 2019

Quick facts

Lead sponsor	Arecor Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	18
Start date	12 April 2019
Primary completion	30 July 2019
Estimated completion	8 August 2019
Sites	1 location across Austria

Drugs / interventions tested

NovoRapid — full drug profile →
Fiasp
AT247 — full drug profile →

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →

Sponsor

Arecor Limited — full company profile →

Who can join

Adults 18 to 64, male only, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase I, randomised, single-centre, double-blind, single-dose, three period, balanced cross over study in a glucose clamp setting. The study compares the pharmacodynamic, pharmacokinetic and safety characteristics of AT247, NovoRapid® and Fiasp® in male participants with type I diabetes mellitus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.
Svehlikova E, Mursic I, Augustin T, Magnes C, et al · · 2021 · cited 13× · PMID 33328285 · DOI 10.2337/dc20-1017

Verify or expand the search:

Other trials of NovoRapid

Trials testing the same drug.

NCT05754424 — AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study · Phase 1 · completed
NCT04660305 — AT278 and NovoRapid® in Glucose Clamp Study · Phase 1 · completed
NCT03328845 — Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) · Phase 4 · completed

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Arecor Limited trials

Trials by the same sponsor.

NCT05754424 — AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study · Phase 1 · completed
NCT05184868 — AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study · Phase 1 · completed
NCT04660305 — AT278 and NovoRapid® in Glucose Clamp Study · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03959514 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arecor Limited
Last refreshed: 30 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03959514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing